164 related articles for article (PubMed ID: 36495594)
1. Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Parker VL; Cushen BF; Hills A; Kandiah K; Palmer JE; Singh K; Hancock BW; Tidy JA; Winter MC
Gynecol Oncol; 2023 Feb; 169():34-40. PubMed ID: 36495594
[TBL] [Abstract][Full Text] [Related]
2. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
Poli JG; Paiva G; Freitas F; Mora P; Velarde LGC; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2021 Sep; 162(3):638-644. PubMed ID: 34266689
[TBL] [Abstract][Full Text] [Related]
3. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
6. Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia.
Korkmaz V; Sunar V; Akar S; Alinca CM; Arik Z; Boran N; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Jun; 18(3):326-332. PubMed ID: 34185962
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors associated with resistance to initial methotrexate treatment in women with low-risk gestational trophoblastic neoplasia.
Phianpiset R; Ruengkhachorn I; Kuljarusnont S; Jareemit N; Udompunturak S
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e495-e506. PubMed ID: 35253996
[TBL] [Abstract][Full Text] [Related]
8. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
[TBL] [Abstract][Full Text] [Related]
9. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R; Lawrie TA
Cochrane Database Syst Rev; 2012 Jul; 7(7):CD007102. PubMed ID: 22786502
[TBL] [Abstract][Full Text] [Related]
10. Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
Mangili G; Cioffi R; Danese S; Frigerio L; Ferrandina G; Cormio G; Rabaiotti E; Scarfone G; Gadducci A; Bergamini A; Pisano C; Candiani M
Gynecol Oncol; 2018 Dec; 151(3):449-452. PubMed ID: 30266260
[TBL] [Abstract][Full Text] [Related]
11. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid.
Taylor F; Grew T; Everard J; Ellis L; Winter MC; Tidy J; Hancock BW; Coleman RE
Eur J Cancer; 2013 Oct; 49(15):3184-90. PubMed ID: 23870384
[TBL] [Abstract][Full Text] [Related]
12. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
[TBL] [Abstract][Full Text] [Related]
13. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
[TBL] [Abstract][Full Text] [Related]
14. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
15. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
16. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
18. Factors related to treatment outcomes in low-risk gestational neoplasia.
Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
[TBL] [Abstract][Full Text] [Related]
19. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
[TBL] [Abstract][Full Text] [Related]
20. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]